Key Highlights of the Portfolio of OS Fund
OS Fund has a portfolio of 42 companies, including 3 unicorns. Their most notable investments are in Verge Genomics and Ginkgo Bioworks.
Their portfolio spans across United States, Canada and United Kingdom. They have invested in High Tech, Life Sciences, Enterprise Applications听补苍诲 20 other sectors, across stages such as Series A, Series B 听补苍诲 2 more.
Here is the list of top investments by OS Fund
Provider of genomics data and cell therapy-based diagnostics and therapeutic solutions. It offers an AI-interfaced platform providing a genomics-based, technology company with creating a database of the whole genome, phenotype, and clinical data. It provides genome sequencing, analysis, and collaboration services for cell therapies, and personalized vaccine development. It offers support services for preventive and personalized care including cancer analysis, integrated health analysis, newborn screening, and rare, undiagnosed diseases.
Key facts about Human Longevity
- Founded Year: 2013
- Location: San Diego (United States)
- Valuation: $310M as on Dec 10, 2018
- Stage: Series B
- Total Funding till date: $409M
- Investors: DFJ, Celgene and 20 Others
- Latest Funding Round: Series B, Aug 22, 2024, $39.8M
- Highlight: Editors' Pick
2. Vicarious
Developer of AI-based robotic arms. It offers solutions for kitting, palletizing, packaging, and wall picking. It also offers robots-as-a-service.
Key facts about Vicarious
- Founded Year: 2010
- Location: San Francisco (United States)
- Stage: Acquired
- Total Funding till date: $250M
- Employee Count: 175 as on Dec 31, 2021
- Investors: Samsung Venture Investment, DCVC and 49 Others
- Latest Funding Round: Series D, Jul 25, 2017, $50M
- Highlight: Acquired
Provider of gene editing-based cultured ingredients for agriculture industry. It specializes in producing microbes for cultured ingredients such as flavors, fragrances, cosmetics, and sweeteners.
Key facts about Ginkgo Bioworks
- Founded Year: 2008
- Location: Boston (United States)
- Annual Revenue: 鈧�18.9K as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $796M
- Employee Count: 1,218 as on Dec 31, 2023
- Investors: General Atlantic, T. Rowe Price and 46 Others
- Latest Funding Round: Grant (prize money), Dec 13, 2023
- Highlight: Public
4. Elysium
Developer and manufactures of cellular health supplements. The products help in a daily formulation for repairing key metabolic processes, including DNA repair, cellular toxicity, energy production, and protein folding. It contains two compounds found in nature that are nicotinamide riboside (NR), a precursor to NAD+, and pterostilbene, a polyphenol.
Key facts about Elysium
- Founded Year: 2014
- Location: New York City (United States)
- Valuation: $157M as on Dec 06, 2016
- Stage: Series C
- Total Funding till date: $71.2M
- Investors: SVB, Western Technology Investment and 18 Others
- Latest Funding Round: Series C, Sep 21, 2021
- Highlight: Editors' Pick
5. Synthego
Developer of CRISPR-engineered cell and gene therapies. Their flagship product "CRISPR evolution", is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Its products include CRISPR/Cas9 EZ RNA kit in either a single guide RNA format, or a two-part tracrRNA format and optional chemical modifications, full-length synthetic RNAs, and screening libraries based on the CRISPRevolution platform. It uses extensive automation in its production pipeline. The company is working in collaboration with many universities to conduct CRISPR research in applications such as stem cells, primary human cells, and mouse embryos.
Key facts about Synthego
- Founded Year: 2012
- Location: Redwood City (United States)
- Stage: Series E
- Total Funding till date: $460M
- Investors: Wellington, RA Capital Management and 30 Others
- Latest Funding Round: Series E, Feb 17, 2022, $200M
- Highlight: Editors' Pick
